SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-22-007075
Filing Date
2022-06-17
Accepted
2022-06-17 16:25:58
Documents
13
Period of Report
2022-06-14
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_061422.htm   iXBRL 8-K 35444
2 AMENDED AND RESTATED BYLAWS OF THE COMPANY ex3-1.htm EX-3.1 133850
  Complete submission text file 0001387131-22-007075.txt   377820

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE admp-20220614.xsd EX-101.SCH 2998
4 XBRL LABEL FILE admp-20220614_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE admp-20220614_pre.xml EX-101.PRE 22385
7 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_061422_htm.xml XML 3702
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 221024218
SIC: 2834 Pharmaceutical Preparations